TEDA-based CanSinoBIO Signed Agreement with SPIMACO of Saudi

On March 25th, TEDA-based CanSinoBIO signed a vaccine collaboration agreement with SPIMACO, a Saudi Arabian pharmaceutical manufacturer. The two sides will jointly promote the access of tetravalent meningococcal vaccine Menhycia® into Saudi Arabia and other markets in the Middle East and North Africa, and also prompt joint R&D and localized production systems. This move marks a major breakthrough in CanSinoBIO’s globalization strategy of the biological markets of the Middle East and North Africa. It also injects strong impetus into the new ecosystem of biopharmaceutical cooperation between China and Saudi Arabia.

CanSinoBIO, a high-tech biological leader established in TEDA in 2009, is committed to the R&D, production and commercialization of human vaccines. The company has five innovative vaccine technology platforms including virus vector vaccine technology, synthetic vaccine technology, protein structure design and VLP assembly technology, mRNA vaccine technology, preparation and drug delivery technology. It has introduced a number of innovative vaccine products covering more than 10 indications. The tetravalent meningococcal conjugate vaccine signed this time is suitable for infants aged 3 months to 3 years (47 months), which has protected over one million children in China and obtained Indonesian marketing license and halal certification.